A *Lactobacillus rhamnosus* strain induces protection in different sites after *Salmonella enterica* subsp. *enterica* serovar Typhimurium challenge in gnotobiotic and conventional mice

[*Uma cepa de* Lactobacillus rhamnosus *induz proteção em diferentes sítios em camundongos gnotobióticos e convencionais após desafio com* Salmonella enterica *subsp.* enterica sorovar *Typhimurium*]

A.H. *Mendonça*[1], M.M.O.P. *Cerqueira*[1*], J.R. *Nicoli*[2], S.M.M. *Sousa*[1], R.M.D. *Nardi*[2], F.N. *Souza*[1], L. M. *Fonseca*[1], M.O. *Leite*[1], R.M.E. *Arantes*[2]

[1]Escola de Veterinária − Universidade Federal de Minas Gerais − Belo Horizonte, MG
[2]Instituto de Ciências Biológicas − Universidade Federal de Minas Gerais− Belo Horizonte, MG

ABSTRACT

The ability of a *Lactobacillus rhamnosus* strain isolated from a healthy breast-fed human newborn to reduce the pathological consequences for the host due to an experimental oral infection with *Salmonella enterica* subsp. *enterica* serov. Typhimurium *in vivo* was determined using gnotobiotic and conventional mice. Conventional mice received 0.1mL probiotic milk (8.0 log colony-forming unit) daily for 10 days before the oral pathogenic challenge (5.0 log colony-forming unit). Then probiotic treatment was continued until the end of the experiment. Probiotic treatment in germ-free mice consisted of a single dose of the probiotic milk at the beginning of the experiment and a challenge with *S.* Typhimurium 10 days later (3.0 log colony-forming unit). A protective effect was observed in both gnotobiotic and conventional animals in terms of histopathologic and morphometric data, but in different anatomical sites. This protection was observed in liver and intestines, respectively, for gnotobiotic and conventional mice. However, *S.* Typhimurium populations were similar in the feces of both treated and control gnotobiotic mice. We conclude that a protective effect of *L. rhamnosus* against experimental *S.* Typhimurium was observed. This protection was not due to the reduction of the population of pathogenic bacteria in the intestine.

Keywords: intestinal infection, lactobacilli, probiotics, *Salmonella*

RESUMO

A habilidade de uma cepa de Lactobacillus rhamnosus *isolada de um recém-nascido saudável de reduzir as consequências patológicas para o hospedeiro após infecção experimental por* Salmonella enterica *subsp.* enterica *sorov. Typhimurium foi avaliada em camundongos gnotobióticos e convencionais. Os camundongos convencionais receberam 0,1mL de leite probiótico por dia (0,8 log unidade formadora de colônia), 10 dias antes do desafio oral com* S. Typhimurium *(5,0 log unidade formadora de colônia), e continuaram recebendo probiótico até o término do experimento. O tratamento com probiótico nos camundongos gnotobióticos consistiu em uma única dose de leite probiótico no início do experimento e desafio oral após 10 dias (3,0 log unidade formadora de colônia). Em termos histopatológicos e morfométricos, a proteção foi observada no fígado e nos intestinos nos animais gnotobióticos e convencionais, respectivamente. No entanto, a população de* S. Typhimurium *foi similar em ambos os grupos tratado e controle de animais gnotobióticos. Desta forma, conclui-se que a proteção conferida pela cepa de* L. rhamnosus *contra o desafio experimental* S. Typhimurium *foi observada em diferentes sítios anatômicos nos animais convencionais e gnotobióticos e que essa proteção não foi devido à redução da população de* S. Typhimurium *nos intestinos.*

Palavras-chave: infecção intestinal, lactobacilos, probióticos, Salmonella

INTRODUCTION

Salmonella enterica subsp. *enterica* serov. Typhimurium are important facultative intracellular pathogens that are implicated in human foodborne illnesses and often enter the human food supply via contamination of poultry, pork, beef and dairy products (Burkholder and Bhunia, 2009). In humans, *Salmonella* spp. is responsible for over one billion infections annually, with consequences ranging from self-limiting gastroenteritis to typhoid fever. A wide range of antimicrobials are used to treat salmonellosis, however, genetic mutations and selective pressure have induced *Salmonella* spp. to become resistant or multi-resistant to these antimicrobials (Martins *et al.*, 2010).

The widespread prescription of antimicrobials not only led to an increase in the antimicrobial-resistant bacterial pathogen strains, but is also often associated with the disruption of the protective microbiota, leading to predisposition to infections. For these reasons, the control of infections through a non-antimicrobial approach is urgently needed (Forestier *et al.*, 2001; Shu and Gill, 2002). It has long been acknowledged that fermented milk-based diets, such as yogurt, can confer enhanced resistance against infection with enteric pathogens to individuals. This enhanced resistance is thought to be effected by the presence of probiotics, therefore certain probiotic strains may be a useful dietary supplement to combat enteric pathogens in humans and animals (Shu and Gill, 2002; Robinson *et al.*, 2010).

Probiotics are food or pharmaceutical preparations containing "live non-pathogenic microorganisms which, when administrated in adequate amounts, confers a health benefit to the host" (FAO/WHO, 2002). The potential mechanisms by which probiotic agents might exert their protective or therapeutic effect against infections include: antagonism by the production of substances which inhibit or kill the pathogen; competition with the pathogen for adhesion sites or nutritional sources; immunomodulation of the host; and inhibition of the production or action of bacterial toxin (Robinson *et al.*, 2010). The likely contribution of each of these mechanisms is difficult to determine in the presence of a broad and complex gastrointestinal microbiota. The use of the gnotobiotic animal model with a simplified intestinal microbial status allows the *in vivo* observation of interactions between a probiotic, a pathogenic bacterium and the host (Silva *et al.*, 1999).

The *Lactobacillus rhamnosus* strain used in the present study was isolated at the Federal University of Minas Gerais from a breast-fed healthy newborn with the objective of isolating a new probiotic for human use. This strain showed antagonistic properties against enteropathogenic bacteria by both *in vitro* and *ex vivo* (inhibitory zone around feces from gnotobiotic mice monoassociated with *L. rhamnosus*) assays, in our previous experiments.

Thus, the aim of the present study was to investigate if this *L. rhamnosus* strain can antagonize *Salmonella enterica* subsp. *enterica* serov. Typhimurium, *in vivo*, and consequently reduce the pathological consequences for the host using gnotobiotic and conventional mice.

MATERIAL AND METHODS

Germ-free 21-day-old NIH mice (Taconic, Germantown, USA) were used in this work. The animals were housed in flexible plastic isolators (Standard Safety Equipment Company, McHenry, USA) and handled according to the established procedures (Pleasants, 1974). Experiments with gnotobiotic mice were carried out in micro-isolators (UNO Roestvaststaal B.V., Zevenaar, The Netherlands). Conventional NIH mice were derived from the germ-free colony and used onlyafter at least two generations following the conventionalization. Water and commercial autoclavable diet (Nuvital, Curitiba, Brazil) were sterilized by steam and administered *ad libitum* to all the animals. Conventional mice were maintained in an open animal house, and controlled lighting (12 h light, 12 h dark) was used for all the animals. All experimental procedures were carried out according to the standards set forth in the "Guide for the Care and Use of Laboratory Animals" from the National Research Council (National…, 1996).

Each gnotobiotic and conventional group consisted of 10 and 30 mice, respectively. Population levels of the pathogenic bacteria and *L. rhamnosus* in the feces of gnotobiotic mice and cumulative mortality for all the animals were recorded during the challenge experiments. At

348

Arq. Bras. Med. Vet. Zootec., v.66, n.2, p.347-354, 2014

the end of the experiments, all remaining mice were sacrificed by cervical dislocation.

The *Lactobacillus rhamnosus* strain used in the present study was isolated from a healthy breast-fed human newborn at the Federal University of Minas Gerais, Belo Horizonte, Brazil, and maintained at - 86°C in de Man, Rogosa and Sharp (MRS) broth (Difco, Sparks, USA) supplemented with 15% glycerol. *Salmonella enterica* subsp. *enterica* serov. Typhimurium was obtained from Fundação Ezequiel Dias (FUNED, Belo Horizonte, Brazil) and maintained at - 70°C in brain heart infusion (BHI) broth (Difco) containing 20% glycerol.

Fermented milk was prepared from 10% reconstituted skim milk inoculated with a 2% culture of *L. rhamnosus* in MRS broth (Difco) and incubated at 37°C during 20 hours. A single dose of fermented milk (0.1mL) containing about 8.0 log of colony-forming units (CFU) of *L. rhamnosus* was administered to germ-free mice by intragastric intubation 10 days before the experimental challenge with pathogenic bacteria. The same dose was administered daily to conventional mice, 10 days before the challenge and during the remaining experimental period. The control conventional and gnotobiotic groups were treated with 0.9% saline according to the same schedule as the corresponding experimental groups.

S. Typhimurium was grown in BHI broth (Difco) at 37°C during 24-48 hours under aerobic conditions. Mice were inoculated through the intragastric route with 0.1mL of the bacterial suspension containing 3.0 or 5.0 log CFU for gnotobiotic or conventional mice, respectively.

Freshly collected feces from gnotobiotic mice were immediately introduced in an anaerobic chamber (Forma Scientific, Marietta, USA, containing an atmosphere of 85% N_2, 10% H_2 and 5% CO_2), diluted 100-fold in saline and vortexed. Serial 10-fold dilutions were performed and 0.1 mL plated onto McConkey agar (Difco) for *S.* Typhimurium and MRS agar (Merck, Darmstadt, Germany) for *L. rhamnosus* and incubated at 37°C for 24–48 hours for bacterial counts under aerobic or anaerobic conditions, respectively.

Tissue samples from different regions of the liver and intestines of mice sacrificed at the end of the experiments were fixed in buffered 4% formaldehyde and processed for paraffin embedding. The histopathological sections (3-5µm) were stained with hematoxylin-eosin. The slides were coded and examined by a single pathologist, who was unaware of the experimental conditions of each group. For morphometric examination of the liver, the images were obtained by a JVC TK-1270/RGB microcamera and the KS 300 Software built in a Kontron Elektronick/Carl Zeiss image analyzer (Oberkohen, Germany). The inflammatory foci were considered as a damage index for hepatic tissue. Inflammatory focus is defined as the accumulation of inflammatory cells in number higher than 10 cells, accompanied by necrotic alterations of the associated parenchyma. The unit of inflammatory foci measured in all animals is the sum of ten 10x- objective fields.

The statistical significance of the results was evaluated by the Student's *t* test, Fisher exact test or Mann-Whitney Rank test depending on the data. The level of significance was set at $P \leq 0.05$. Statistical analyses were performed using the Sigma Stat program (Jandel Scientific Software, version 1.0, San Rafael, CA, USA).

RESULTS

A better preservation of the hepatic tissue was observed in the treated group (Fig. 1b) when compared to control animals (Fig. 1a) from gnotobiotic mices after the pathogenic challenge. This fact was confirmed by a higher ($P<0.05$) number of inflammatory foci in the gnotobiotic control group when compared to its treated counterpart (Fig. 2). In the intestines of gnotobiotic animals, lesions were similar between treated and control mice (data not shown) and characterized by intense destruction of ileal and colonic mucosa, fusion of colonic glandula, crypt abscesses, inflammatory infiltrate of stroma and congestion.

*Arq. Bras. Med. Vet. Zootec.*, v.66, n.2, p.347-354, 2014

349

Figure 1. Histopathological aspect of the liver from gnotobiotic control (a) and treated (b) mice after challenge with *Salmonella* Typhimurium. Arrows show inflammatoty foci. Hematoxilin-eosin (350X).


Figure 2. Number of inflammatory foci in the liver of gnotobiotic mice treated with *Lactobacillus rhamnosus* (GLF) or untreated gnotobiotic mice (GGS) after challenge with *Salmonella* Typhimurium (*$P<0.05$).

L. rhamnosus became established in the digestive tract of gnotobiotic mice and the population level was about 9.0 log CFU/g of feces (Fig. 3). After the challenge with the pathogen, the *L. rhamnosus* fecal population decreased to levels between 6.0 to 7.0 log CFU/g of feces. *Salmonella* Typhimurium became similarly established in the digestive tract of both treated and control mice with numbers ranging from 7.0 to 9.0 log CFU/g of feces and remained at these high numbers until the animals died or were sacrificed in treated and control gnotobiotic mice (Fig. 3).

Figure 3. Fecal levels (log CFU/mL) of *Lactobacillus rhamnosus* (■) and *Salmonella* Typhimurium (Δ) in gnotobiotic mice treated with fermented milk, and fecal levels of *S.* Typhimurium (◆) in the untreated gnotobiotic mice .

In conventional animals, hepatic lesions were similar between treated and control mice and there was no significant difference ($P > 0.05$) for number of inflammatory foci between the two groups (Fig. 4). On the other hand, more severe lesions were observed in the intestines of conventional control animals when compared to the treated ones (Fig. 5). However, accumulated mortality was similar for the two groups (data not shown), both under gnotobiotic and conventional conditions.


Figure 4. Number of inflammatory foci in the liver of conventional mice treated with *Lactobacillus rhamnosus* (GLF) or untreated conventional mice (GCS) after the challenge with *Salmonella* Typhimurium.

Figure 5. Histopathological aspect of ileum from treated (a) and untreated control (b) conventional mice after the challenge with *Salmonella* Typhimurium. Hematoxylin-eosin (140X).

DISCUSSION

Lactobacilli have the longest history of use as probiotics and are still the most common ingredients for preparations intended for consumption by human beings and animals. Like other probiotics, *L. rhamnosus* was drastically eliminated from the digestive tract of mammals harbouring a complex intestinal microbiota and for this reason the daily ingestion of these microorganisms was necessary to maintain high artificial levels in the gastrointestinal ecosystem of conventional animals. Thus, it is interesting to think of probiotics as altering community susceptibility to invasion without necessarily becoming permanent residents of the community (Silva *et al.*, 1999; Robinson *et al.*, 2010). On the other hand, its implantation was possible in germ-free animals using a single dose. Gnotobiotic mice were then used in the present study to obtain a simplified *in vivo* ecosystem allowing the observation of ecological interactions between the probiotic and the bacterial pathogen. The results were compared with those obtained using a similar experimental design, but with animals harboring a indigenous gastrointestinal microbiota (conventional) (Silva *et al.*, 1999).

As expected and observed with other probiotics, the protection offered by *L. rhamnosus* against the pathogenic challenge was different between conventional and gnotobiotic animals due to the complementary protective effect from the indigenous intestinal microbiota and the biotherapeutic agent in the first case. Germ-free animals are extremely susceptible to experimental infection due to both the lack of ecological competition in the gastrointestinal lumen and to the underdeveloped immune system in the internal compartment (Rodrigues *et al.*, 1996; Silva *et al.*, 1999; Tham *et al.*, 2011). This fact can explain, at least in part, the differences observed in the intestine protection in conventional and gnobiotic mice.

Additionally, the similar severity of intestinal lesions in treated and control gnotobiotic animals can be explained, at least in part, by the dyscrepancy of the primary sites of *S.* Typhimurium invasion and the antagonism effect of the lactobacilli used here. It is described that *in vivo* the terminal ileum is the primary site of *S.* Typhimurium invasion (Hudalt *et al.*, 1997; Filho-Lima *et al.*, 2000). However, Peyer's patches and M cells of the small intestine are the first to be involved (Hudalt *et al.*, 1997). With this in mind, it should be noted that the microbial interactions differ in distinct sites. For instance, some lactobacilli strains can reduce drastically the *E. coli* population in the stomach of gnotobiotic mice, although the effect on the large intestine was significantly lower (Freter, 1992). Conversely, our previous *ex-vivo* experiments in gnotobiotic mice demonstrated that the diameter of the inhibition zone produced by *L. rhamnosus* against *S.* Typhimurium was not different in the distinc sites of the digestive tract (duodenum, jenunum, ileum, cecum, colon and feces).

A protective effect of *L. rhamnosus* against experimental *S.* Typhimurium was observed here and this protection was not due to the reduction of the population of pathogens in the intestine as demonstrated here by the similar population levels of the *Salmonella* in the feces from treated

352

Arq. Bras. Med. Vet. Zootec., v.66, n.2, p.347-354, 2014

and control gnotobiotic mice (Fig. 3). However, in our previous *in vitro* and *ex vivo* experiments, the *L. rhamnosus* strain used here showed antagonistic properties against *S.* Typhimurium. A reduction in the population of the probiotic microorganism decreased after inoculation of *Salmonella* Typhimurium, as observed here, with *L. rhamnosus* strains as described by Salva *et al.* (2010).

Here we observed a lower number of inflammatory foci in the liver of treated gnotobiotic mice when compared to control gnotobiotic animals, although the hepatic lessions were similar in conventional animals (Fig. 4). This protection observed in treated gnotobiotic mice can be due to the reduced translocation of *S.* Typhumurium as proposed by other probiotics (Martins *et al.*, 2007; Martins *et al.*, 2010; Salva *et al.*, 2010). This fact can be explained, at least in part, by the inhibition of both cell association and cell entry of this enterobacterium as described with other lactobacilli strains in enterocyte-like Caco-2 cells (Hudalt *et al.*, 1997; Xu *et al.*, 2009). With this in mind, Miyauchi *et al.* (2009) demonstrated that the *L. rhamnosus* OLL2838 is effective for the suppression of the tumor necrosis factor (TNF)-α-induced barrier impairment in Caco-2 cells and dextran sodium sulfate-induced colitis in mice. In addition, Perdigon *et al.* (1988) demonstrated that the treatment of mice with *L. casei* suspension for three days stimulated the anti-*Salmonella* immunoglobulin-A antibodies and decreased the number of *S.* Typhimurium cells in the liver and spleen. Shu and Gill (2002) also observed that the previous supplementation with *L. rhamnosus* HN001 in mice challenged with *Escherichia coli* O157:H7 reduced the mortality rates and the pathogenic bacteria translocation rates and increased the anti-*E.* coli immunoglobulin-A titers and phagocytic rates, suggesting that the protection was due to cellular and humoral immunomodulation responses.

While the humoral response is important in protecting against intracellular pathogens, the cellular immunity is crucial (Bao *et al.*, 2000; Salva *et al.*, 2010). Interferon (IFN)-γ produced by T cells and natural killer cells have shown to play an important role in the host defense against intracellular pathogens such as *S.* Typhimurium (Bao *et al.*, 2000). Salva *et al.* (2010) described a significant increase in IFN-γ in serum and

intestinal fluid of mice fed with *L. rhamnosus* CRL1505 and *L. rhamnosus* CRL1506 strains. *In vitro* studies have shown that epithelial cells and fibroblasts are resistant to *S.* Typhimurium invasion in the presence of IFN-γ, which activated mouse epithelial macrophages, resulting in enhanced *S.* Typhimurium killing (Salva *et al.*, 2010). Therefore, it is important to note that each *Lactobacillus* strain has specific properties and that its effect on the host's health cannot be extrapolated to other strains (Fayol-Messaoudi *et al.*, 2005; Burkholder and Bhunia, 2009; Salva *et al.*, 2010).

CONCLUSIONS

The *L. rhamnosus* strain used in the present study presented a potential probiotic use, however, futher studies are needed to determine the mechanisms by which this *L. rhamnosus* strain modulated the *S.* Typhimurium infection.

ACKNOWLEDGMENTS

REFERENCES

BAO, S.; BEAGLEY, K.W.; FRANCE, M.P. *et al.* Interferon-gamma plays a critical role in intestinal immunity against *Salmonella typhimurium* infection. *Immunology*, v.99, p.464-472, 2010.

BURKHOLDER, K.M.; BHUNIA, A.K. *Salmonella enterica* serovar Typhimurium adhesion and cytotoxicity during epithelial cell stress is reduced by *Lactobacillus rhamnosus* GG. *Gut Pathog.*, v.1, p.14, 2009.

FAO/WHO. *Guidelines for the evaluation of probiotics in food*. Canada: London Ontario, 2002.

FAYOL-MESSAOUDI, D.; BERGER, C.N.; COCONNIER POLTER, M.H. *et al.* pH-, Lactic Acid-, and Non-lactic Acid-Dependent Activities of Probiotic Lactobacilli against *Salmonella enterica* serovar Typhimurium. *Appl. Environ. Microbiol.*, v.71, p.6008-6013, 2005.

Arq. Bras. Med. Vet. Zootec., v.66, n.2, p.347-354, 2014

353

FILHO-LIMA, J.V.M.; VIEIRA, E.C.; NICOLI, J.R. Antagonistic effect of *Lactobacillus acidophilus*, *Saccharomyces boulardii* and *Escherichia coli* combinations against experimental infections with *Shigella flexneri* and *Salmonella enteritidis* subsp. Typhimurium in gnotobiotic mice. *J. Appl. Microbiol.*, v.88, p.365-370, 2000.

FORESTEIR, C.; DE CHAMPS, C.; VATOUX, C.; JOLY, B. Probiotic activities of *Lactobacillus casei rhamnosus*: *in vitro* adherence to intestinal cells and antimicrobial properties. *Res. Microbiol.*, v.152, p.167-173, 2001.

FRETER, R. Factors affecting the microecology of the gut. In: FULLER, R. (Ed). *Probiotics*: the scientific basis. London: Chapman & Hall, 1992. p.111-143.

HUDALT, S.; LIÉVIN, V.; BERNET-CAMARAD, M.F.; SERVIN, A. Antagonistic activity exerted *in vitro* and *in vivo* by *Lactobacillus casei* (strain GG) against *Salmonella* Typhimurium C5 infection. *Appl. Environ. Microbiol.*, v.63, p.513-518, 1997.

MARTINS, F.S.; DALMASSO, G.; ARANTES, R.M.E. *et al.* Interaction of *Saccharomyces boulardi* with *Salmonella enterica* serovar Typhimurium protects mice and modifies T84 cell response to the infection. *PloS One*, v.5:e8925, 2010.

MARTINS, F.S.; RODRIGUES, A.C.P.; TIAGO, F.C.P. *et al. Saccharomyces cerevisiae* strain 905 reduces the translocation of *Salmonella enterica* serotype Typhimurium and stimulates the immune system in gnotobiotic and conventional mice. *J. Med. Microbiol.*, v.56, p.352-359, 2007.

MIYAUCHI, E.; MORITA, H.; TANABE, S. *Lactobacillus rhamnosus* alleviates intestinal barrier dysfunction in part by increasing expression of zonula occludens-1 and myosin light-chain kinase *in vivo*. *J. Dairy Sci.*, v.92, p.2400-2408, 2009.

NATIONAL Research Council. Guide for the Care and Use of Laboratory Animals. Washington: National Academy Press, 1996. 246p.

PERDIGON, G.; ALVAREZ, S.; MEDICI, M. Systemic and local augmentation of the immune response in mice by feeding with milk fermented with *Lactobacillus acidophilus* and/or *Lactobacillus casei*. *Immunology*, v.63, p.17-23, 1988.

PLEASANTS, J.R Gnotobiotics. In: MELBY JR., E.C.; ALTMANN, E.C. (Ed.) *Handbook of Laboratory Animal Science*. Clevand: CRC Press, 1974. p.119-174.

ROBINSON, C.J.; BOHANNAN, B.J.M.; YOUNG, V.B. From structure to function: the ecology of host-associated microbial communities. *Microbiol. Mol. Biol. R.*, v.74, p.453-476, 2010.

RODRIGUES, A.C.P.; NARDI, R.M.; BAMBIRRA, E.A. *et al.* Effect of *Saccharomyces boulardii* against experimental oral infection with *Salmonella typhimurium* and *Shigella flexneri* in conventional and gnotobiotic mice. *J. Appl. Bacteriol.*, v.81, p.251-256, 1996.

SALVA, S.; VILLENA, J.; ALVAREZ, S. Immunomodulatory activity of *Lactobacillus rhamnosus* isolated from goat milk: Impact on intestinal and respiratory infections. *Int. J. Food Microbiol.*, v.141, p.82-89, 2010.

SILVA, A.M.; BAMBIRRA, E.A.; OLIVEIRA, A.L. *et al.* Protective effect of bifidus milk on the experimental infection with *Salmonella enteritidis* subsp. Typhimurium in conventional and gnotobiotic mice. *J. Appl. Microbiol.*, v.86, p.331-336, 1999.

SHU, Q.; GILL, H.S. Immune protection mediated by the probiotic *Lactobacillus rhamnosus* HN001 (DR20TM) against *Escherichia coli* O157:H7 infection in mice. *FEMS Immunol. Med. Microb.*, v.34, p.59-64, 2002.

THAM, C.S-C.; PEH, K-K.; BHAT, R.; LIONG, M-T. Probiotic properties of bifidobacteria and lactobacilli isolated from local dairy products. *Ann. Microbiol.*, v.62, p.1079, 2011.

XU, H.; JEONG, H.S.; LEE, H.Y.; AHN, J. Assessment of cell surface properties and adhesion potential of selected probiotic strains. *Lett. Appl. Microbiol.*, v.49, p.434-442, 2009.

354

Arq. Bras. Med. Vet. Zootec., **v.66, n.2, p.347-354, 2014**